Skip to main content
SpringerLink
Log in

Multimodality Imaging in Cardiac Amyloidosis

  • Echocardiography (JM Gardin and AH Waller, Section Editors)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Cardiac amyloidosis is an increasingly recognized condition with a growing range of targeted therapies, but diagnosis requires a high index of suspicion and multimodality imaging expertise. Early diagnosis remains key to improving quality of life and survival. This article reviews the multimodality imaging approach to the diagnosis, differentiation, and prognosis of cardiac amyloidosis.

Recent Findings

Recent advances in multimodality cardiac imaging have allowed for earlier diagnosis of cardiac amyloidosis resulting in earlier initiation of life-saving therapy in cases of light chain amyloidosis and life-prolonging therapy in transthyretin amyloidosis.

Summary

With these advances in multimodality imaging, it is important for cardiologists and cardiac imagers to be aware of the subtleties of early disease, the appropriate diagnostic approach as well as understanding the practicalities and pitfalls that are encountered with each modality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336(7):466–73.

    Article  CAS  PubMed  Google Scholar 

  2. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–94.

    Article  CAS  PubMed  Google Scholar 

  3. . Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12 Seminal paper assessing utility of technetium-labeled radiotracers for non-biopsy diagnosis of ATTR cardiac amyloidosis.

    Article  CAS  PubMed  Google Scholar 

  4. Falk RH, Plehn JF, Deering T, Schick EC Jr, Boinay P, Rubinow A, et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol. 1987;59(5):418–22.

    Article  CAS  PubMed  Google Scholar 

  5. Alashi A, Desai RM, Khullar T, Hodges K, Rodriguez ER, Tan C, et al. Different histopathologic diagnoses in patients with clinically diagnosed hypertrophic cardiomyopathy after surgical myectomy. Circulation. 2019;140(4):344–6.

    Article  PubMed  Google Scholar 

  6. Falk RH, Quarta CC, Dorbala S. How to image cardiac amyloidosis. Circ Cardiovasc Imaging. 2014;7(3):552–62.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Damy T, Jaccard A, Guellich A, Lavergne D, Galat A, Deux JF, et al. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis. Amyloid. 2016;23(3):194–202.

    Article  CAS  PubMed  Google Scholar 

  8. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70(4):466–77.

    Article  CAS  PubMed  Google Scholar 

  9. Feng D, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009;119(18):2490–7.

    Article  CAS  PubMed  Google Scholar 

  10. Modesto KM, Dispenzieri A, Cauduro SA, Lacy M, Khandheria BK, Pellikka PA, et al. Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. Eur Heart J. 2005;26(2):173–9.

    Article  PubMed  Google Scholar 

  11. Falk RH, Alexander KM, Liao R, Dorbala S. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68(12):1323–41.

    Article  PubMed  Google Scholar 

  12. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107(19):2446–52.

    Article  PubMed  Google Scholar 

  13. Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, et al. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC Cardiovasc Imaging. 2019;12(5):823–33 Study demonstrating prognostic roles of echo and CMR parameters, which also describes the functional and structural cardiac abnormalities that occur across a spectrum of cardiac amyloid burden in AL and ATTR cardiac amyloidosis, as measured by ECV.

    Article  PubMed  Google Scholar 

  14. Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442–8.

    Article  PubMed  Google Scholar 

  15. Liu D, Hu K, Niemann M, Herrmann S, Cikes M, Stork S, et al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6(6):1066–72.

    Article  PubMed  Google Scholar 

  16. Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J, et al. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging. 2017;10(3):e005588 Compared the diagnostic accuracy of various deformation and conventional echo parameters in differentiating CA from other hypertrophic substrates.

    Article  PubMed  Google Scholar 

  17. Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985;6(4):737–43.

    Article  CAS  PubMed  Google Scholar 

  18. Bodez D, Ternacle J, Guellich A, Galat A, Lim P, Radu C, et al. Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid. 2016;23(3):158–67.

    Article  CAS  PubMed  Google Scholar 

  19. Mohty D, Pibarot P, Dumesnil JG, Darodes N, Lavergne D, Echahidi N, et al. Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis. Arch Cardiovasc Dis. 2011;104(12):611–8.

    Article  PubMed  Google Scholar 

  20. Klein AL, Hatle LK, Taliercio CP, Oh JK, Kyle RA, Gertz MA, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation. 1991;83(3):808–16.

    Article  CAS  PubMed  Google Scholar 

  21. Barros-Gomes S, Williams B, Nhola LF, Grogan M, Maalouf JF, Dispenzieri A, et al. Prognosis of light chain amyloidosis with preserved LVEF: added value of 2D speckle-tracking echocardiography to the current prognostic staging system. JACC Cardiovasc Imaging. 2017;10(4):398–407.

    Article  PubMed  Google Scholar 

  22. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–93.

    Article  PubMed  Google Scholar 

  23. White JA, Kim HW, Shah D, Fine N, Kim KY, Wendell DC, et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):143–56.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94(12):3318–26.

    Article  CAS  PubMed  Google Scholar 

  26. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):155–64.

    Article  PubMed  Google Scholar 

  27. Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):133–42.

    Article  PubMed  Google Scholar 

  28. Cuddy SAM, Bravo PE, Falk RH, El-Sady S, Kijewski MF, Park MA, et al. Improved Quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease? JACC Cardiovasc Imaging. 2020;13(6):1325–36.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Dorbala S, Vangala D, Bruyere J Jr, Quarta C, Kruger J, Padera R, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2(4):358–67.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Ferreira VM, Piechnik SK, Dall’Armellina E, Karamitsos TD, Francis JM, Choudhury RP, et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:42.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Dass S, Suttie JJ, Piechnik SK, Ferreira VM, Holloway CJ, Banerjee R, et al. Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging. 2012;5(6):726–33.

    Article  PubMed  Google Scholar 

  32. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):157–65.

    Article  PubMed  Google Scholar 

  33. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4):488–97.

    Article  PubMed  Google Scholar 

  34. Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36(4):244–51.

    Article  PubMed  Google Scholar 

  35. Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2019;12(5):810–9 This study evaluated the prognostic potential of native myocardial T1 in cardiac transthyretin amyloidosis (ATTR) and compared native T1 with extracellular volume (ECV) in terms of diagnostic accuracy and prognosis.

    Article  PubMed  Google Scholar 

  36. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson. 2017;19(1):75.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6(1):34–9.

    Article  PubMed  Google Scholar 

  38. Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging. 2012;5(9):897–907.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol. 2018;71(25):2919–31.

    Article  PubMed  Google Scholar 

  40. Martinez-Naharro A, Abdel-Gadir A, Treibel TA, Zumbo G, Knight DS, Rosmini S, et al. CMR-verified regression of cardiac AL amyloid after chemotherapy. JACC Cardiovasc Imaging. 2018;11(1):152–4 Small longitudinal study showing decrease in amyloid burden by ECV.

    Article  PubMed  Google Scholar 

  41. Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging. 2021;14(1):189–99.

    Article  PubMed  Google Scholar 

  42. Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol. 2016;25(5):413–7.

    Article  CAS  PubMed  Google Scholar 

  43. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–84.

    Article  PubMed  Google Scholar 

  44. . Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Card Fail. 2019;25(11):e1–e39 Expert Consensus Recommendations for multimodality imaging of amyloidosis, with a comprehensive review of literature in the field.

    Article  PubMed  Google Scholar 

  45. Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15(11):1289–98.

    Article  PubMed  Google Scholar 

  46. Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6(2):195–201.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1(8):880–9.

    Article  PubMed  Google Scholar 

  48. Hanna M, Ruberg FL, Maurer MS, Dispenzieri A, Dorbala S, Falk RH, et al. Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week. J Am Coll Cardiol. 2020;75(22):2851–62 Important review highlighting common errors in scan acquisition and interpretation that can lead to misdiagnosis of ATTR.

    Article  CAS  PubMed  Google Scholar 

  49. Dewanjee MK, Kahn PC. Mechanism of localization of 99mTc-labeled pyrophosphate and tetracycline in infarcted myocardium. J Nucl Med. 1976;17(7):639–46.

    CAS  PubMed  Google Scholar 

  50. Azevedo Coutinho MC, Cortez-Dias N, Cantinho G, Goncalves S, Menezes MN, Guimaraes T, et al. The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease. Amyloid. 2020;27(3):174–83.

    Article  CAS  PubMed  Google Scholar 

  51. Mockelind S, Axelsson J, Pilebro B, Lindqvist P, Suhr OB, Sundstrom T. Quantification of cardiac amyloid with [(18)F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis. Amyloid. 2020;27(3):191–9.

    Article  PubMed  Google Scholar 

  52. Chang ICY, Bois JP, Bois MC, Maleszewski JJ, Johnson GB, Grogan M. Hydroxychloroquine-mediated cardiotoxicity with a false-positive 99mtechnetium-labeled pyrophosphate scan for transthyretin-related cardiac amyloidosis. Circ Cardiovasc Imaging. 2018;11(1):e007059. https://doi.org/10.1161/CIRCIMAGING.117.007059.

  53. Scully PR, Patel KP, Treibel TA, Thornton GD, Hughes RK, Chadalavada S, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41(29):2759–67 Study showing prevalence of disease in AS cohort.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol. 2018;72(17):2040–50.

    Article  PubMed  Google Scholar 

  55. Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study. J Nucl Med. 2016;57(11):1733–9.

    Article  CAS  PubMed  Google Scholar 

  56. Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652–62.

    Article  CAS  PubMed  Google Scholar 

  57. Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54(2):213–20.

    Article  CAS  PubMed  Google Scholar 

  58. Gallegos C, Miller EJ. Advances in PET-based cardiac amyloid radiotracers. Curr Cardiol Rep. 2020;22(6):40.

    Article  PubMed  Google Scholar 

  59. Castano A, DeLuca A, Weinberg R, Pozniakoff T, Blaner WS, Pirmohamed A, et al. Serial scanning with technetium pyrophosphate ((99m)Tc-PYP) in advanced ATTR cardiac amyloidosis. J Nucl Cardiol. 2016;23(6):1355–63.

    Article  PubMed  Google Scholar 

  60. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203–12.

    Article  CAS  PubMed  Google Scholar 

  61. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982;49(1):9–13.

    Article  CAS  PubMed  Google Scholar 

  62. Helder MR, Schaff HV, Nishimura RA, Gersh BJ, Dearani JA, Ommen SR, et al. Impact of incidental amyloidosis on the prognosis of patients with hypertrophic cardiomyopathy undergoing septal myectomy for left ventricular outflow tract obstruction. Am J Cardiol. 2014;114(9):1396–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine, Heart & Vascular Centre, Brigham and Women’s Hospital and Harvard Medical School, 15 Francis St, Boston, MA, 02115, USA

    Gerard T. Giblin & Sarah A. M. Cuddy

  2. CV Imaging Program, Cardiovascular Division and Department of Radiology, Brigham and Women’s Hospital, Boston, USA

    Sarah A. M. Cuddy

Authors
  1. Gerard T. Giblin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah A. M. Cuddy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah A. M. Cuddy.

Ethics declarations

Conflict of Interest

GG: No conflicts of interest to declare.

SC: Investigator-initiated research grant from Pfizer.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Echocardiography

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giblin, G.T., Cuddy, S.A.M. Multimodality Imaging in Cardiac Amyloidosis. Curr Cardiol Rep 23, 134 (2021). https://doi.org/10.1007/s11886-021-01564-6

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11886-021-01564-6

Keywords

Search

Navigation